Goldman Sachs And Hedge Funds See Big Things For These Small-caps

3. Zeltiq Aesthetics Inc (NASDAQ:ZLTQ)

 – Investors with Long Positions (as of June 30): 26

 – Aggregate Value of Investors’ Holdings (as of June 30): $352.13 Million

– Goldman Sachs Rating and Price Target: ‘Buy’ $43 (34% upside to the current trading level)

The total June end hedge fund holdings accounted for a hefty 31% of the company’s market cap. So far this year Zeltiq Aesthetics Inc (NASDAQ:ZLTQ)’s stock price has surged by more than 15%, even though this development is not entirely captured by the sentiment during the second quarter as number of hedge funds holding the company in their portfolios only grew by one and the total value of these investments increased merely by one million. Aisling Capital, which is led by Dennis Purcell heads this list of investors with some 2.60 million shares.

Although the $1.21 billion medical technology company helping freeze off stubborn fat cells with its CoolSculpting machines posted a 37% increase in its top line during the second quarter compared with the year-ago number, it also marked the weakest growth since the 2013 June quarter. While it is still to be seen whether the growth trajectory will continue to tone down, Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) is in terrific shape as far as the company’s fundamentals are concerned.